Enhanced Cancer Therapeutic Methods Utilizing Modified OPCML Fragments

The present inventive concept relates to improved cancer therapeutic methods utilizing modified OPCML fragments with enhanced tumor suppressor activity, targeted delivery, and personalized treatment approaches.

The original patent disclosed the role of OPCML in cancer prognosis, theragnosis, treatment, and research, but had limitations in terms of efficacy, delivery, and patient selection. The present inventive concept addresses these limitations by introducing modified OPCML fragments with improved tumor suppressor activity, conjugated to nanoparticles for targeted delivery, and personalized treatment approaches based on patient genetic profiles and tumor characteristics.

The inventive concept comprises a system for cancer treatment utilizing a polypeptide comprising a modified fragment of OPCML, which exhibits improved tumor suppressor activity compared to the unmodified fragment. Additionally, the inventive concept includes methods for enhancing the efficacy of OPCML-based cancer therapy by administering the modified fragment in combination with a chemotherapeutic agent. Furthermore, the inventive concept encompasses compositions for treating cancer, wherein the modified fragment is conjugated to a nanoparticle for targeted delivery to cancer cells. The inventive concept also includes methods for identifying patients likely to respond to OPCML-based cancer therapy by analyzing biological samples for expression levels of OPCML and/or its downstream targets. Moreover, the inventive concept comprises a system for personalized cancer treatment, wherein the modified fragment is selected based on the patient's genetic profile and/or tumor characteristics.

The novelty of the present inventive concept lies in the modification of the OPCML fragment to enhance its tumor suppressor activity, the conjugation of the modified fragment to nanoparticles for targeted delivery, and the personalized treatment approaches based on patient genetic profiles and tumor characteristics. The inventive step is the combination of these features, which provides a significant improvement over the original patent.

Alternative embodiments of the inventive concept could include the use of different types of nanoparticles, varying the conjugation methods, or utilizing different chemotherapeutic agents. Variations of the inventive concept could also include the use of different genetic profiles or tumor characteristics for personalized treatment approaches.

The present inventive concept has significant commercial potential in the cancer therapeutic market, with potential applications in treating various types of cancer, including HER2-positive and HER2-negative cancer tumors. The targeted delivery and personalized treatment approaches could provide a competitive advantage in the market, with potential partnerships with pharmaceutical companies, research institutions, and hospitals.